VBL Therapeutics Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Vascular Biogenics (VBLT) Tops Q1 EPS by 8c
May 12, 2015 8:55 AM EDTVascular Biogenics (NASDAQ: VBLT) reported Q1 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23).
Cash, cash equivalents and short term deposits as of March 31, 2015 were $34.4 million, compared to $36.8 million at year end 2014.
For earnings history and earnings-related data on Vascular Biogenics (VBLT) click here.
... More